They found that patients responding to ICIs had increased numbers of intratumoral and peritumoral CD8+ T cells together with higher numbers of PD-L1+ cells, both before therapy and in tumor biopsies collected early after therapy, thus confirming data obtained with IHC (20, 21). Here, CD8A is linked to neoplasm.